Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD8205 |
Synonyms | |
Therapy Description |
AZD8205 is a an antibody-drug conjugate (ADC) comprising a B7-H4 targeted antibody linked to a topoisomerase inhibitor, which potentially leads to apoptosis of B7-H4-expressing tumor cells and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1765). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD8205 | AZD 8205|AZD-8205 | AZD8205 is a an antibody-drug conjugate (ADC) comprising a B7-H4 targeted antibody linked to a topoisomerase inhibitor, which potentially leads to apoptosis of B7-H4-expressing tumor cells and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1765). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05123482 | Phase Ib/II | AZD8205 | First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies | Recruiting | USA | POL | NLD | ITA | HUN | GBR | ESP | CAN | BEL | AUS | 5 |